A Study to Compare Different Intubating Doses of Zemuron in Pediatric and Adolescent Subjects Under General Anesthesia
Completed
Merck Sharp & Dohme Corp.
Phase 3
2004-12-01
The primary purpose of this study is to evaluate the time course of muscle relaxation after
administration of three different single intravenous bolus doses of rocuronium bromide for
intubation (insertion of a tube through the nose or mouth into the trachea to provide
artificial ventilation) in term neonates (birth to
A Study to Determine the Dose Requirements of Rocuronium Bromide (Zemuron®) in Pediatric and Adolescent Subjects (21048)(COMPLETED)(P05797)
Completed
Merck Sharp & Dohme Corp.
Phase 3
2004-10-01
The primary purpose of this study is to determine the dose requirements of rocuronium bromide
when administered as a bolus dose (a single, large dose) for intubation (insertion of a tube
through the nose or mouth into the trachea to provide artificial ventilation) and when
administered by either continuous infusion or bolus doses for maintenance of muscle
relaxation in term neonates (birth to
Dose-Finding Pediatric and Adult Trial With Sugammadex (Org 25969, MK-8616, SCH 900616) (19.4.306) (MK-8616-034) (P05961)
Completed
Merck Sharp & Dohme Corp.
Phase 3
2005-05-30
The purpose of this study is:
- to explore the dose-response relation of sugammadex (Org 25969, MK-8616, SCH 900616)
given as a reversal agent at reappearance of T2 after 0.6 mg.kg-1 rocuronium in
pediatric and adult participants
- to explore the pharmacokinetics (PK) of sugammadex in pediatric and adult participants,
and to evaluate the safety of sugammadex in pediatric and adult participants.
Dose-Finding Trial With Sugammadex Administered at 3 and 15 Minutes After 1.0 and 1.2 mg/kg Rocuronium Bromide in Participants of ASA Class 1-3 (P05944; MK-8616-024)
Completed
Merck Sharp & Dohme Corp.
Phase 2
2004-03-04
The objective of this trial was to explore the dose-response relation of sugammadex (Org
25969; MK-8616) administered for the reversal of neuromuscular blockade (NMB) at 3 and 15
minutes following administration of 1.0 and 1.2 mg/kg of Esmeron® (rocuronium) in
participants receiving surgery, classified as American Society of Anesthesiologists (ASA)
class 1 (otherwise normal, healthy participant), class 2 (participant with mild systemic
disease), or class 3 (participant with a severe systemic disease that limits activity, but is
not incapacitating).
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors.
Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data.
The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free.
We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models.
By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice.
thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user.
Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
Alerts Available With Subscription
Alerts are available for users with active subscriptions.
